Overview

Effect of Vitamin D Supplement on Disease Activity in SLE

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

To study the effect of vitamin D supplementation on disease activity of SLE ( SLEDAI-2K ) and IL-6 level

Phase:

N/A

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Rajavithi Hospital

Treatments:

Ergocalciferols
Vitamin D

Criteria

Inclusion Criteria:

- Age > 18 year-old

- SLE classified by revised ACR criteria, SLICC 2012 criteria

- SLE patients who have mild to moderate disease activity ( clinical SLEDAI-2K 3-10 )
and has vitamin D level < 40 ng/ml

- currently treated with stable dose of 1 or more of the following background medication
: NSAIDs, anti-malarial, MMF, Azathioprine, methotrexate, cyclosporin for at least 1
month, corticosteroid weeks

- received calciferol 20,000 IU/wk (1 cap) at least 12 weeks

Exclusion Criteria:

- patients with chronic liver disease, CKD stage 3, bed ridden, malignancy

- patients who received drug that interfere with vitamin D metabolism

- poor drug compliance

- overlap with other connective tissue disease or a diagnosis of MCTD

- hx of vitamin D allergy

- hx on MTV or other supplementation